Literature DB >> 28339425

Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma.

Takamichi Ito1, Gaku Tsuji1,2, Fumitaka Ohno1, Takeshi Nakahara1,3, Hiroshi Uchi1, Masutaka Furue1,2,3.   

Abstract

OVOL1 and OVOL2 are ubiquitously conserved genes encoding C2H2 zinc-finger transcription factors in mammals. They promote epithelial cell proliferation, differentiation, and mesenchymal-to-epithelial transition, coordinately mediated via the Wnt signaling pathway. We previously reported that human OVOL1 and OVOL2 were preferentially expressed in the normal epidermis and hair follicles as well as their tumors, and found that OVOL1 is upregulated in Bowen's disease and downregulated in cutaneous squamous cell carcinoma. The aims of this study were to elucidate the potential role of the OVOL1-OVOL2 axis in Bowen's disease and squamous cell carcinoma, and to reveal the relationship between OVOL and c-Myc, a proto-oncogene that plays a pivotal role in the malignancy of epithelial tumors. We investigated 20 Bowen's disease and 20 squamous cell carcinoma clinical samples and a human squamous cell carcinoma cell line (A431) using immunohistochemical staining and molecular biological approaches. Immunohistochemical analysis revealed that OVOL1 was upregulated in Bowen's disease and markedly downregulated in squamous cell carcinoma; conversely, c-Myc was downregulated in Bowen's disease and upregulated in squamous cell carcinoma. OVOL2 was markedly upregulated in the nucleus of Bowen's disease cells, but the distribution of OVOL2 expression in squamous cell carcinoma varied widely; OVOL2 was typically expressed in the cytoplasm, but only sporadically in the nucleus. Furthermore, knockdown of OVOL1 using a specific small interfering RNA increased the mRNA and protein levels of c-Myc and OVOL2. Knockdown of OVOL2 did not significantly affect the mRNA and protein levels of either c-Myc or OVOL1. These results suggest that OVOL1 is an upstream suppressor of c-Myc and OVOL2, and the OVOL1-OVOL2 axis is a modulator of c-Myc, coordinately regulating the invasiveness of cutaneous squamous cell carcinoma. Taken together, this study suggests that the OVOL1-OVOL2 axis is a key modulator of c-Myc expression in the shift from in situ epidermal malignancy (Bowen's disease) to invasive squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28339425     DOI: 10.1038/modpathol.2016.169

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  Ovol2 suppresses cell cycling and terminal differentiation of keratinocytes by directly repressing c-Myc and Notch1.

Authors:  Julie Wells; Briana Lee; Anna Qianyao Cai; Adrine Karapetyan; Wan-Ju Lee; Elizabeth Rugg; Satrajit Sinha; Qing Nie; Xing Dai
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

2.  Epithelial tumor, invasion and stroma.

Authors:  Masutaka Furue
Journal:  Ann Dermatol       Date:  2011-05-27       Impact factor: 1.444

Review 3.  The ins and outs of the epithelial to mesenchymal transition in health and disease.

Authors:  M Angela Nieto
Journal:  Annu Rev Cell Dev Biol       Date:  2011-07-08       Impact factor: 13.827

4.  Strain-dependent perinatal lethality of Ovol1-deficient mice and identification of Ovol2 as a downstream target of Ovol1 in skin epidermis.

Authors:  Andy Teng; Mahalakshmi Nair; Julie Wells; Julia A Segre; Xing Dai
Journal:  Biochim Biophys Acta       Date:  2006-09-12

Review 5.  What real influence does the proto-oncogene c-myc have in OSCC behavior?

Authors:  Mario Pérez-Sayáns; José Manuel Suárez-Peñaranda; Gayoso-Diz Pilar; Francisco Barros-Angueira; José Manuel Gándara-Rey; Abel García-García
Journal:  Oral Oncol       Date:  2011-06-25       Impact factor: 5.337

6.  Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.

Authors:  D H Jensen; E Dabelsteen; L Specht; A M K Fiehn; M H Therkildsen; L Jønson; J Vikesaa; F C Nielsen; C von Buchwald
Journal:  J Pathol       Date:  2015-06-01       Impact factor: 7.996

Review 7.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

Review 8.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

9.  Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor.

Authors:  Kazuhide Watanabe; Alvaro Villarreal-Ponce; Peng Sun; Michael L Salmans; Magid Fallahi; Bogi Andersen; Xing Dai
Journal:  Dev Cell       Date:  2014-04-14       Impact factor: 12.270

Review 10.  Wnt some lose some: transcriptional governance of stem cells by Wnt/β-catenin signaling.

Authors:  Wen-Hui Lien; Elaine Fuchs
Journal:  Genes Dev       Date:  2014-07-15       Impact factor: 11.361

View more
  13 in total

Review 1.  Molecular and cytoskeletal regulations in epidermal development.

Authors:  Jimmy Lee; Philbert Lee; Xiaoyang Wu
Journal:  Semin Cell Dev Biol       Date:  2017-05-31       Impact factor: 7.727

2.  Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway.

Authors:  Xuewei Sun; Zhiyuan Li; Yanfang Niu; Lijuan Zhao; Yichuan Huang; Qiang Li; Shengnan Zhang; Ting Chen; Tao Fu; Tao Yang; Xiaofei An; Yan Jiang; Jisheng Zhang
Journal:  Cell Prolif       Date:  2019-05-31       Impact factor: 6.831

3.  Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis.

Authors:  Takamichi Ito; Yumiko Kaku-Ito; Maho Murata; Toshio Ichiki; Yuki Kuma; Yuka Tanaka; Taketoshi Ide; Fumitaka Ohno; Maiko Wada-Ohno; Yuichi Yamada; Yoshinao Oda; Masutaka Furue
Journal:  Int J Mol Sci       Date:  2019-12-08       Impact factor: 5.923

4.  OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.

Authors:  Xue-Kang Qi; Hui-Qiong Han; Hao-Jiong Zhang; Miao Xu; Lili Li; Lin Chen; Tong Xiang; Qi-Sheng Feng; Tiebang Kang; Chao-Nan Qian; Mu-Yan Cai; Qian Tao; Yi-Xin Zeng; Lin Feng
Journal:  Theranostics       Date:  2018-03-08       Impact factor: 11.556

5.  Ovol2 induces mesenchymal-epithelial transition via targeting ZEB1 in osteosarcoma.

Authors:  Jijun Liu; Qi Wu; Yonggui Wang; Yulong Wei; Hong Wu; Lijun Duan; Qiang Zhang; Yonggang Wu
Journal:  Onco Targets Ther       Date:  2018-05-22       Impact factor: 4.147

Review 6.  Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis.

Authors:  Masutaka Furue
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

7.  Upregulation of FLG, LOR, and IVL Expression by Rhodiola crenulata Root Extract via Aryl Hydrocarbon Receptor: Differential Involvement of OVOL1.

Authors:  Akiko Hashimoto-Hachiya; Gaku Tsuji; Mika Murai; Xianghong Yan; Masutaka Furue
Journal:  Int J Mol Sci       Date:  2018-06-04       Impact factor: 5.923

8.  Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival.

Authors:  Takamichi Ito; Yumiko Kaku-Ito; Maho Murata; Kazuhisa Furue; Che-Hung Shen; Yoshinao Oda; Masutaka Furue
Journal:  J Clin Med       Date:  2020-03-04       Impact factor: 4.241

9.  The Transcription Factor OVOL2 Represses ID2 and Drives Differentiation of Trophoblast Stem Cells and Placental Development in Mice.

Authors:  Mariyan J Jeyarajah; Gargi Jaju Bhattad; Dendra M Hillier; Stephen J Renaud
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

10.  Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of OVOLs in Breast Cancer.

Authors:  Jingsheng Chen; Hongjun Tang; Taidong Li; Kangwei Jiang; Haiming Zhong; Yuye Wu; Jiangtao He; Dongbing Li; Mengzhen Li; Xingsheng Cai
Journal:  Int J Gen Med       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.